On June 20, 2024, the California Supreme Court made an important decision that changes how pharmaceutical and medical device companies can be held responsible for not warning about the risks of their products.
Theresa had 32 ECT sessions in 1989 and experienced severe memory loss, cognitive problems, and a decline in her quality of life. Her letter to the FDA (Docket #82P-0316) urges the FDA to keep the ECT device at class III.
Kimberley shares thoughts on her journey through 400+ ECT treatments, reflecting on her experience of loss and personal resilience.
Documents from the Atze Akkerman and Elizabeth Akkerivian v. Mecta Corp case, 2004.
A critical look at a study that claims ECT appears to be a low risk treatment.
This article discusses the challenges faced by individuals with cognitive disabilities after undergoing electroconvulsive therapy (ECT). The author draws on personal experiences and research to highlight issues such as societal perception and limited support from social services.